Recombinant Guinea pig Voltage-dependent L-type calcium channel subunit alpha-1C (CACNA1C)-VLPs

What is the basic structure of the recombinant guinea pig CACNA1C protein?

Recombinant guinea pig CACNA1C protein is a fragment protein spanning amino acids 1-169 of the full-length voltage-dependent L-type calcium channel subunit alpha-1C. It is typically expressed in cell-free systems with ≥85% purity and is suitable for SDS-PAGE analysis . The protein sequence begins with FQEQGEQEYKNCELDKNQRQ and includes critical domains involved in voltage sensing and ion channel formation. CACNA1C is the pore-forming α1C subunit that gives rise to L-type calcium currents in excitable cells. The "L" designation refers to "long-lasting," describing the extended activation period characteristic of these channels .

What are the primary physiological roles of CACNA1C channels?

CACNA1C channels serve multiple critical physiological functions:

• Cardiac function: Mediates excitation-contraction coupling in cardiomyocytes by triggering calcium-induced calcium release from the sarcoplasmic reticulum

• Vascular regulation: Essential for normal blood pressure regulation via contraction of arterial smooth muscle cells

• Gastrointestinal function: Required for normal contraction of smooth muscle cells in the intestine

• Neuronal signaling: Regulates neurohormones and neurotransmitter release in neurons

• Development: Required for normal heart development and regulation of heart rhythm

Additionally, CACNA1C plays roles in gene expression, mRNA stability, neuronal survival, and synaptic efficacy .

What are the optimal expression systems for producing recombinant guinea pig CACNA1C for research applications?

For functional studies requiring fully assembled channels, mammalian expression systems co-expressing auxiliary subunits (β and α2δ) are recommended to ensure proper trafficking and electrophysiological properties.

What are the key considerations when designing electrophysiological experiments to study CACNA1C channel function?

When designing electrophysiological experiments to study guinea pig CACNA1C channels:

• Voltage protocols: Design protocols based on the known biophysical properties. L-type calcium channels are high-voltage activated, requiring substantial depolarization for activation. Typical activation threshold is around -30mV .

• Recording solutions:

  • External solution should contain physiological or elevated Ca²⁺ (2-10mM) or Ba²⁺ (5-20mM)

  • Internal solution should contain Cs⁺ to block K⁺ channels and EGTA/BAPTA for Ca²⁺ buffering

• Pharmacological tools:

  • Dihydropyridines (e.g., nifedipine) for selective L-type channel blockade

  • Use Bay K 8644 as an L-type channel agonist for enhanced current detection

• Temperature considerations: Record at physiological temperature (37°C) when possible, as channel kinetics are temperature-dependent

• Expression systems: When heterologously expressing channels, co-express auxiliary subunits (β, α2δ) for proper trafficking and function

Remember that L-type channels display calcium-dependent inactivation, so consider using Ba²⁺ as the charge carrier to minimize this effect when studying voltage-dependent properties.

How can CACNA1C be incorporated into virus-like particles (VLPs) for research applications?

Incorporating CACNA1C into VLPs represents an advanced approach for studying channel structure and function. While the provided search results don't specifically address CACNA1C-VLPs, the following methodological approach can be considered:

• Selection of VLP scaffold: Choose an appropriate viral capsid protein that allows surface display, such as hepatitis B core antigen (HBcAg) or bacteriophage Qβ.

• Fusion strategy: Design genetic constructs that fuse specific domains of CACNA1C (rather than the full-length protein) to VLP subunits:

  • N-terminal fusion: May preserve CACNA1C domain structure but can affect VLP assembly

  • C-terminal fusion: Often better for VLP assembly but may constrain CACNA1C domain folding

  • Internal insertion: Place CACNA1C domains in surface-exposed loops of VLP proteins

• Expression and purification:

  • Express in appropriate systems (mammalian, insect, or yeast cells)

  • Purify using density gradient ultracentrifugation and size-exclusion chromatography

  • Verify assembly by electron microscopy and dynamic light scattering

• Functional validation:

  • Confirm CACNA1C domain exposure using immunological methods

  • Assess binding to known interaction partners

  • Evaluate potential channel formation using liposome reconstitution experiments

This approach can be valuable for presenting CACNA1C epitopes in a multivalent format for immunological studies or for developing novel research tools to study calcium channel biology.

How do genetic polymorphisms in CACNA1C affect cardiovascular treatment responses?

Genetic polymorphisms in CACNA1C have significant implications for personalized cardiovascular treatment approaches. Research from the International Verapamil SR Trandolapril Study identified a critical polymorphism that influences treatment outcomes :

This pharmacogenetic interaction suggests that genotyping CACNA1C variants could guide more personalized treatment selection in patients with hypertension and stable coronary artery disease . The polymorphism affects the gene encoding the α1c subunit of L-type calcium channels, which is the binding site for all currently available calcium channel blockers. While the exact molecular mechanism remains unclear (ventricular expression and mRNA splicing analyses did not reveal the functional basis), these findings represent an important step toward precision medicine in cardiovascular disease management.

What role does CACNA1C play in neurological development and related disorders?

CACNA1C plays crucial roles in neurological development, with disruption leading to significant consequences. Studies using forebrain-specific Cacna1c knockout mice revealed:

• Altered calcium signaling: Disrupted Cacna1c gene expression perturbs spontaneous Ca²⁺ activity in the developing neocortex

• Behavioral phenotypes: Cacna1c knockout mice exhibit:

  • Significant behavioral inhibition

  • Altered exploratory behavior in novel environments

  • Anxiety-related behaviors in open field and elevated plus maze tests

• Neuronal development impacts: CACNA1C contributes to:

  • Neuronal survival

  • Synaptic efficacy

  • Protection against ischemic-induced axonal injury

  • Regulation of gene expression and mRNA stability in neurons

These findings suggest that CACNA1C dysfunction may contribute to neurodevelopmental and neuropsychiatric disorders characterized by altered neuronal connectivity and anxiety-related behaviors. The calcium signaling mediated by CACNA1C appears essential for proper brain development and function, making it an important target for research into neurological and psychiatric conditions.

How can recombinant CACNA1C be used to study calcium channel modulation at the molecular level?

Recombinant CACNA1C provides a powerful tool for investigating calcium channel modulation through several advanced approaches:

• Site-directed mutagenesis studies:

  • Introduce specific mutations in key residues to identify drug binding sites

  • Modify phosphorylation sites to study regulation by kinases

  • Create chimeric channels with other calcium channel subtypes to identify subtype-specific properties

• Structural biology approaches:

  • Use purified recombinant fragments for X-ray crystallography or cryo-EM studies

  • Perform hydrogen-deuterium exchange mass spectrometry to identify dynamic regions

  • Apply molecular dynamics simulations to understand conformational changes

• Protein-protein interaction studies:

  • Identify regulatory proteins that interact with specific CACNA1C domains

  • Map interaction sites using truncated constructs

  • Develop competitive inhibitors of specific protein-protein interactions

• Phosphorylation studies:

  • Map phosphorylation sites using mass spectrometry

  • Study the functional consequences of phosphorylation on channel properties

  • Identify the kinases and phosphatases that regulate channel function

These approaches can reveal fundamental mechanisms of calcium channel modulation that may lead to novel therapeutic strategies for cardiovascular, neurological, and other disorders involving calcium signaling.

What are the biophysical properties of guinea pig CACNA1C channels compared to other species?

Guinea pig CACNA1C channels display distinct biophysical properties that make them valuable models for cardiovascular and neurological research. While the search results don't provide direct comparative data for guinea pig L-type channels specifically, we can extrapolate from related information:

Guinea pig models are particularly valuable for cardiac research as they exhibit action potential profiles more similar to humans than mouse or rat models, especially regarding repolarization characteristics and response to cardioactive drugs.

How do L-type calcium channels interact with other calcium channel subtypes in native tissues?

In native tissues, L-type calcium channels (including CACNA1C) operate within complex networks of multiple calcium channel subtypes with distinct but complementary roles:

• Neuronal systems: In myenteric neurons of guinea pig small intestine, L-type channels contribute approximately 56% of the total calcium current when studied with specific blockers (nifedipine, ω-conotoxin GVIA, and ω-agatoxin IVA) . The remaining current is primarily carried by R-type calcium channels, which contribute about 46% when studied in isolation . This suggests functional overlap and potential compensatory mechanisms.

• Cardiac tissue: In cardiomyocytes, L-type channels are predominant at the T-tubules and trigger calcium-induced calcium release by activating ryanodine receptor 2 (RyR2), causing calcium release from the sarcoplasmic reticulum . Their phosphorylation increases calcium permeability and myocyte contractility.

• Vascular smooth muscle: L-type channels are essential for vasoconstriction, working alongside T-type channels that may contribute to initial depolarization.

The interactions between channel subtypes create integrated calcium signaling networks with properties that cannot be fully understood by studying individual channel types in isolation. This complexity underlies the often-unpredictable effects of subtype-specific calcium channel modulators in vivo and highlights the importance of studying native systems alongside recombinant models.

What are the major challenges in purifying functional recombinant CACNA1C for structural studies?

Purifying functional recombinant CACNA1C presents several significant challenges:

• Size and complexity: The full-length CACNA1C protein is large (~240 kDa) with multiple transmembrane domains, making heterologous expression and purification difficult.

• Membrane protein nature: As an integral membrane protein, CACNA1C requires detergents or lipid environments for stability, complicating purification procedures.

• Auxiliary subunits: Functional CACNA1C typically requires association with β and α2δ auxiliary subunits for proper folding and trafficking.

• Post-translational modifications: Native CACNA1C undergoes extensive post-translational modifications that may be essential for function but difficult to reproduce in heterologous systems.

Solutions to these challenges include:

• Domain-based approach: Express and purify individual domains rather than full-length protein. The recombinant guinea pig CACNA1C fragment (amino acids 1-169) represents such an approach .

• Advanced expression systems: Use eukaryotic expression systems like insect cells or mammalian cells for better folding and post-translational modifications.

• Fusion tags: Incorporate solubility-enhancing fusion partners like MBP or SUMO to improve expression and purification yields.

• Nanodiscs or amphipols: Employ these membrane-mimetic systems to maintain the native-like environment for the purified protein.

• Co-expression strategies: Express CACNA1C with its auxiliary subunits to promote proper assembly and stability.

How can researchers troubleshoot low expression yields of recombinant CACNA1C?

Low expression yields of recombinant CACNA1C are a common challenge. Here are methodological approaches to troubleshoot and improve yields:

• Optimize codon usage: Adapt codons to the expression host to enhance translation efficiency.

• Screen multiple constructs:

  • Test different domain boundaries and truncations

  • Try various fusion tags (His, GST, MBP, SUMO)

  • Evaluate signal sequence variations for membrane targeting

• Modify expression conditions:

  • Temperature (lower temperatures often improve folding)

  • Induction timing and duration

  • Media composition and supplements

  • Inducer concentration

• Address protein toxicity:

  • Use tightly regulated inducible promoters

  • Try specialized expression strains for toxic proteins

  • Consider cell-free expression systems which have proven effective for guinea pig CACNA1C fragments

• Expression host selection:

  • For fragments: E. coli with solubility-enhancing tags

  • For functional domains: Insect cells or mammalian cells

  • For structural studies: Consider synthetic approaches for specific transmembrane segments

• Protein stabilization strategies:

  • Include channel blockers during expression

  • Co-express with stabilizing interacting proteins

  • Introduce stability-enhancing mutations

The cell-free expression system used for producing the guinea pig CACNA1C fragment (amino acids 1-169) with ≥85% purity demonstrates that this approach can be successful for certain domains .

What are emerging applications of CACNA1C-VLPs in drug discovery and vaccine development?

While the search results don't specifically mention CACNA1C-VLPs, we can project potential applications based on general VLP technology and CACNA1C biology:

• Drug discovery applications:

  • High-throughput screening platforms presenting multiple copies of CACNA1C drug binding domains on VLP surfaces

  • Development of conformation-specific antibodies against CACNA1C using VLPs as immunogens

  • Creation of biosensors by incorporating CACNA1C domains responsive to calcium channel modulators

• Vaccine development potential:

  • Design of therapeutic vaccines targeting autoantibodies against L-type calcium channels in certain autoimmune conditions

  • Development of research tools to study immune responses against calcium channels in pathological conditions

  • Creation of standardized reagents for detecting anti-CACNA1C antibodies in patient samples

• Diagnostic applications:

  • Development of serological assays for detecting autoantibodies against CACNA1C

  • Creation of imaging probes using VLPs displaying CACNA1C domains

• Nanomedicine approaches:

  • Targeted drug delivery using VLPs displaying CACNA1C fragments to tissues with high channel expression

  • Design of cell-specific targeting strategies based on differential expression of CACNA1C variants

These applications represent theoretical extensions of VLP technology to CACNA1C research and would require substantial development and validation.

How might personalized medicine approaches leverage CACNA1C genetic information in the future?

The discovery of CACNA1C polymorphisms that predict differential responses to cardiovascular medications suggests several promising directions for personalized medicine:

• Pharmacogenetic testing in clinical practice:

  • Development of point-of-care genotyping for CACNA1C variants to guide antihypertensive therapy

  • Integration of CACNA1C genotype information into electronic health records with clinical decision support

• Expanded therapeutic applications:

  • Screening for CACNA1C variants that predict response to calcium channel blockers in other conditions, such as migraine, epilepsy, or psychiatric disorders

  • Development of novel drugs targeting specific CACNA1C variants

• Risk stratification models:

  • Incorporation of CACNA1C genotype into cardiovascular risk assessment tools

  • Identification of patients likely to experience adverse effects from specific medications

• Novel therapeutic targets:

  • Development of allele-specific modulators of CACNA1C function

  • Gene therapy approaches to correct deleterious CACNA1C variants

• Comprehensive genetic profiles:

  • Analysis of interactions between CACNA1C variants and other genetic factors

  • Development of polygenic risk scores incorporating CACNA1C and related genes

The current evidence suggests that patients with the A/A genotype might benefit most from calcium channel blockers, while those with the G/G genotype might do better with β-blockers . Future research will need to validate these findings in diverse populations and establish the molecular mechanisms underlying these pharmacogenetic interactions.